What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

(Reuters) -Drugmaker Regeneron Pharmaceuticals is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million. The once-sizzling DNA-testing startup filed for ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

UnitedHealth insiders scooped up shares after the insurer’s stock swooned to a five-year low last week amid mounting federal ...